Evidence map›Paper›PMID 36645406›Full record

ArticleeLife2023

A hierarchy of cell death pathways confers layered resistance to shigellosis in mice.

Justin L Roncaioli, Janet Peace Babirye, Roberto A Chavez, Fitty L Liu, Elizabeth A Turcotte, Angus Y Lee, Cammie F Lesser, Russell E Vance

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. TLR priming licenses NAIP inflammasome activation by immunoevasive ligands.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  13. Article
  14. Review
  15. International journal of molecular sciences · 2024
    Review
  16. Article
  17. mBio · 2023
    Article
  18. bioRxiv : the preprint server for biology · 2023
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Justin L RoncaioliDivision of Immunology & Molecular Medicine, Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States.
Janet Peace BabiryeDivision of Immunology & Molecular Medicine, Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States.
Roberto A ChavezDivision of Immunology & Molecular Medicine, Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States.
Fitty L LiuDivision of Immunology & Molecular Medicine, Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States.
Elizabeth A TurcotteDivision of Immunology & Molecular Medicine, Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States.
Angus Y LeeCancer Research Laboratory, University of California, Berkeley, Berkeley, United States.
Cammie F LesserDepartment of Microbiology, Harvard Medical School, Boston, United States.
Russell E VanceDivision of Immunology & Molecular Medicine, Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States.ORCID 0000-0002-6686-3912
University of California, Berkeley · USBroad Institute · USHoward Hughes Medical Institute · US

Funding

The role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PORTNOY, DANIEL A · 2004 to 2025
$45.5M
Modeling mechanisms of Shigella pathogenesis in yeastR01AI064285 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LESSER, CAMMIE · 2006 to 2017
$4.0M
Functional and Structural Dissection of Inflammasome ActivationR37AI075039 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI RUSSELL E VANCE · 2018 to 2026
$3.8M
Specificity and in vivo function of the Naip/Nlrc4 inflammasomesR01AI075039 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI VANCE, RUSSELL E · 2008 to 2017
$3.6M
Dissection of Shigella pathogenesis in vivo using a new oral infection mouse modelR01AI155634 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI VANCE, RUSSELL E · 2020 to 2024
$2.2M
Shigella suppression of epithelial cell deathR56AI064285 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LESSER, CAMMIE · 2012 to 2022
$948k
Shigella and macrophage cell deathR21AI128743 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LESSER, CAMMIE · 2017 to 2018
$470k
Howard Hughes Medical InstituteNIAID NIH HHS P01 AI063302NIAID NIH HHS R01 AI064285NIAID NIH HHS R01 AI075039NIAID NIH HHS R01 AI155634NIAID NIH HHS R21 AI128743NIAID NIH HHS R37 AI075039NIAID NIH HHS R56 AI064285NIH HHS AI063302NIH HHS AI075039NIH HHS AI155634
6 · The paper itself

Abstract

Bacteria of the genus

Indexed as

Dysentery, BacillaryShigellaAnimalsCaspasesCell DeathInflammasomesMiceShigella flexneriCaspasesInflammasomesimmunologyinfectious diseaseinflammationintestinemicrobiologymousepathogenesisShigella

Identifiers

PMID36645406
PMCPMC9876568
OpenAlexW4316661931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.